Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 64 entries
View as:

Bioequivalence Trial of Pyronaridine Artesunate To-be-marketed Tablet to the Clinical Trial Reference Tablet

Phase: N/A Priority: Normal
NCT ID: NCT00682630 Org: User:
Start: 09/30/07 End: 09/30/08 Due: 09/30/09

Bioavailability Study of Oral OZ439 Prototype Formulations Administered With Piperaquine Phosphate (PQP)

Phase: N/A Priority: Normal
NCT ID: NCT02083406 Org: User:
Start: 07/31/14 End: 07/31/14 Due: 07/31/15

A FIH Study to Investigate the Safety, Tolerability and PK of P218

Phase: N/A Priority: Normal
NCT ID: NCT02885506 Org: User:
Start: 08/24/16 End: 12/04/17 Due: 12/04/18

Determine the Tolerability and Safety of Atovaquone-proguanil (ATV-PG) Co-administered With Amodiaquine (AQ)

Phase: N/A Priority: Normal
NCT ID: NCT04002687 Org: User:
Start: 04/04/19 End: 10/29/19 Due: 10/29/20

Open Label Pharmacokinetic Study of OZ439 and Piperaquine on Administration of OZ439+TPGS Granules for Oral Suspension Alone or With Either Piperaquine Phosphate Tablets or Granules for Oral Solution in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01958619 Org: User:
Start: 10/31/13 End: 01/31/14 Due: 01/31/15

Bioavailability Study of Oral OZ439 Prototype Granule Formulations Administered With Piperaquine Phosphate (PQP) Tablets

Phase: N/A Priority: Normal
NCT ID: NCT02387580 Org: User:
Start: 04/30/15 End: 06/30/15 Due: 06/30/16

Atoguanil BA Study

Phase: N/A Priority: Normal
NCT ID: NCT04866602 Org: User:
Start: 11/17/21 End: 03/18/22 Due: 03/18/23

Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A

Phase: N/A Priority: Normal
NCT ID: NCT02783820 Org: User:
Start: 05/31/16 End: 12/31/16 Due: 12/31/17

Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria

Phase: N/A Priority: Normal
NCT ID: NCT00440999 Org: User:
Start: 03/31/07 End: 09/30/08 Due: 09/30/09

Pyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum Malaria

Phase: N/A Priority: Normal
NCT ID: NCT00331136 Org: User:
Start: 06/30/06 End: 12/31/06 Due: 12/31/07

Phase II Artesunate Study in Severe Malaria

Phase: N/A Priority: Normal
NCT ID: NCT00522132 Org: User:
Start: 09/30/07 End: 12/31/08 Due: 12/31/09

Piperaquine Granule Formulation Relative Bioavailability and Food Effect Study in Healthy Volunteers.

Phase: N/A Priority: Normal
NCT ID: NCT05930782 Org: User:
Start: 08/14/23 End: 01/03/24 Due: 01/03/25

Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru

Phase: N/A Priority: Normal
NCT ID: NCT05361486 Org: User:
Start: 08/28/23 End: 10/31/24 Due: 10/31/25

MMV390048 POC in Patients With P. Vivax and P. Falciparum Malaria

Phase: N/A Priority: Normal
NCT ID: NCT02880241 Org: User:
Start: 10/20/17 End: 09/24/18 Due: 09/24/19

Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum

Phase: N/A Priority: Normal
NCT ID: NCT05979207 Org: User:
Start: 08/01/23 End: 10/30/23 Due: 10/30/24

Absolute BA and OZ439 PK Effect of Different OZ439 Dose Volumes and Cobicistat Co-administration Study

Phase: N/A Priority: Normal
NCT ID: NCT04069221 Org: User:
Start: 02/28/17 End: 05/30/17 Due: 05/30/18

DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax

Phase: N/A Priority: Normal
NCT ID: NCT02123290 Org: User:
Start: 01/31/16 End: 01/31/16 Due: 01/31/17

Experimental Falciparum Transmission to Anopheles

Phase: N/A Priority: Normal
NCT ID: NCT02431637 Org: User:
Start: 04/30/15 End: 09/30/16 Due: 09/30/17

Phase I Study of Ascending Doses of MMV390048 in Healthy Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02230579 Org: User:
Start: 05/31/14 End: 02/28/15 Due: 02/28/16

MMV533 Plasmodium Falciparum Volunteer Infection Study

Phase: N/A Priority: Normal
NCT ID: NCT05205941 Org: User:
Start: 03/30/22 End: 09/02/22 Due: 09/02/23

Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients

Phase: N/A Priority: Normal
NCT ID: NCT00541385 Org: User:
Start: 10/31/07 End: 11/30/08 Due: 11/30/09

Safety, Tolerability and Chemoprotective Activity of P218 in PfSPZ Challenge Model

Phase: N/A Priority: Normal
NCT ID: NCT03707041 Org: User:
Start: 11/16/18 End: 06/03/19 Due: 06/03/20

Safety Tolerability & Pharmacokinetics of Co-administered Single Doses of OZ439 & Piperaquine to Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01660022 Org: User:
Start: 09/30/12 End: 05/31/13 Due: 05/31/14

Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients

Phase: N/A Priority: Normal
NCT ID: NCT00422084 Org: User:
Start: 01/31/07 End: 05/31/08 Due: 05/31/09

Relative Bioavailability of Pyronaridine-artesunate in Tablet and Granule Formulations in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01868438 Org: User:
Start: 05/31/13 End: 01/31/14 Due: 01/31/15